Current Investment Highlights

Enrolment completed in the pivotal LCP-Tacro™ Phase III study in de novo kidney transplant patients. Results from this study are expected mid-2013
Positive results of LCP-Tacro Phase III "Switch" Study
Exclusive distribution agreement with Chiesi Farmaceutici S.p.A for the commercialization and distribution of LCP-Tacro™ in certain countries, including Europe, Turkey and CIS countries
Submission of marketing authorization Application (MAA) in April 2013 to the European Medicines Agency (EMA) seeking approval to market LCP-Tacro for the prevention of organ rejection in kidney transplant patients in the European Union
Financing in place to support development, differentiation and commercialization activities through initial launch of LCP-Tacro
Full organizational focus on the completion of the development and subsequent commercialization of LCP-Tacro™
Preliminary analysis of the STRATO Phase lllb study suggests reduction in tremor following the switch from twice-daily tacrolimus to once-daily LCP-Tacro™

Expected 2013 Milestones

Veloxis anticipates releasing final results from its STRATO tremor study in May 2013
The pivotal study results from the 3002 kidney transplant study are on target for release in mid-2013 with expected NDA filing with the FDA in the second half of 2013. If successful, and if approved by EMA and FDA, commercialization of LCP-Tacro could begin by approximately the fourth quarter 2014